UNSPSC 51144100: Stimulant or anorexiant amphetamines

This classification denotes substances that block adrenergic and dopamine uptake, inhibit monoamine oxidase, and stimulate monamine release, central nervous system stimulators, called amphetamines, that tend to increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT AMPHETAMINES.

UNSPSC 51144100 Stimulant or anorexiant amphetamines is a Class code that in recent state and local procurement activity does not align with its nominal pharmaceutical scope. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems (opioid-reversal harm-reduction supplies), a pharmacy benefit manager direct-contracting RFI for general prescription fulfillment, and a multi-state cooperative purchasing agreement for generic pharmaceuticals and OTC products — none of which center on stimulant or anorexiant amphetamine procurement. The mismatch suggests either miscoding at the issuing body or a data-tagging misalignment. State and local health agencies, pharmacy benefit programs, and cooperative purchasing alliances (specifically MMCAP, the Minnesota Multistate Cooperative Purchasing Alliance) are the primary issuing bodies soliciting under this code's label, though their actual procurement scope diverges from the code's definition.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building; the procurement includes FEMA funding and requires E-Verify compliance, workers' compensation insurance, and commercial general liability coverage. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler channels. MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110 and 112, and Morris & Dickson), with price competitiveness weighted at 75 percent of evaluation and contract effectiveness July 1, 2026. Vendors pursuing these opportunities should verify code alignment with issuing bodies before submitting, as the current tagging does not reflect the actual pharmaceutical and harm-reduction products being solicited.